A group of 20-member macrolactones in which there are three remotely substituted pyran rings that are linked by a methylene bridge and an E-disubstituted alkene, and have geminal dimethyls at C8 and C18 carbons. Some interact with PROTEIN KINASE C.
A phylum of small sessile aquatic animals living as small tufted colonies. Some appear like hydroids or corals, but their internal structure is more advanced. Most bryozoans are matlike, forming thin encrustations on rocks, shells, or kelp. (Storer & Stebbins, General Zoology, 6th ed, p443)
Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES.
A group of often glycosylated macrocyclic compounds formed by chain extension of multiple PROPIONATES cyclized into a large (typically 12, 14, or 16)-membered lactone. Macrolides belong to the POLYKETIDES class of natural products, and many members exhibit ANTIBIOTIC properties.
Changing an open-chain hydrocarbon to a closed ring. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.
Tumor-promoting compounds obtained from CROTON OIL (Croton tiglium). Some of these are used in cell biological experiments as activators of protein kinase C.
A group of the proteobacteria comprised of facultatively anaerobic and fermentative gram-negative bacteria.
A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems.
An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters.
The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.
The relationship between two different species of organisms that are interdependent; each gains benefits from the other or a relationship between different species where both of the organisms in question benefit from the presence of the other.
A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors. (1/250)

Bryostatin-1 belongs to the family of macrocyclic lactones isolated from the marine bryozoan Bugula neritina and is a potent activator of protein kinase C (PKC). Bryostatin has been demonstrated to possess both in vivo and in vitro anti-leukaemic potential. In samples derived from chronic myeloid leukaemia (CML) patients, it has been demonstrated that bryostatin-1 induces a macrophage differentiation, suppresses colony growth in vitro and promotes cytokine secretion from accessory cells. We investigated the effect of bryostatin-1 treatment on colony-forming unit-granulocyte macrophage (CFU-GM) capacity in the presence of accessory cells, using mononuclear cells, as well as in the absence of accessory cells using purified CD34-positive cells. Cells were obtained from 14 CML patients as well as from nine controls. Moreover, CD34-positive cells derived from CML samples and controls were analysed for stem cell frequency and ability using the long-term culture initiating cell (LTCIC) assay at limiting dilution. Individual colonies derived from both the CFU-GM and LTCIC assays were analysed for the presence of the bcr-abl gene with fluorescence in situ hybridization (FISH) to evaluate inhibition of malignant colony growth. The results show that at the CFU-GM level bryostatin-1 treatment resulted in only a 1.4-fold higher reduction of CML colony growth as compared to the control samples, both in the presence and in the absence of accessory cells. However, at the LTCIC level a sixfold higher reduction of CML growth was observed as compared to the control samples. Analysis of the LTCICs at limiting dilution indicates that this purging effect is caused by a decrease in output per malignant LTCIC combined with an increase in the normal stem cell frequency. It is concluded that bryostatin-1 selectively inhibits CML growth at the LTCIC level and should be explored as a purging modality in CML.  (+info)

Identification of sibling species of the bryozoan Bugula neritina that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "Candidatus Endobugula sertula". (2/250)

Although the cosmopolitan marine bryozoan Bugula neritina is recognized as a single species, natural products from this bryozoan vary among populations. B. neritina is the source of the anticancer drug candidate bryostatin 1, but it also produces other bryostatins, and different populations contain different bryostatins. We defined two chemotypes on the basis of previous studies: chemotype O contains bryostatins with an octa-2,4-dienoate substituent (including bryostatin 1), as well as other bryostatins; chemotype M lacks bryostatins with the octa-2,4-dienoate substituent. B. neritina contains a symbiotic gamma-proteobacterium "Candidatus Endobugula sertula," and it has been proposed that bryostatins may be synthesized by bacterial symbionts. In this study, B. neritina populations along the California coast were sampled for genetic variation and bryostatin content. Colonies that differ in chemotype also differ genetically by 8% in the mitochondrial cytochrome c oxidase subunit 1 (CO I) gene; this difference is sufficient to suggest that the chemotypes represent different species. Each species contains a distinct strain of "E. sertula" that differs at four nucleotide sites in the small subunit ribosomal RNA (SSU rRNA) gene. These results indicate that the chemotypes have a genetic basis rather than an environmental cause. Gene sequences from an Atlantic sample matched sequences from the California chemotype M colonies, suggesting that this type may be cosmopolitan due to transport on boat hulls.  (+info)

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. (3/250)

Bryostatin-1, a macrocyclic lactone, appears to elicit a wide range of biological responses including modulation of protein kinase C (PKC). PKC, one of the major elements in the signal transduction pathway, is involved in the regulation of cell growth, differentiation, gene expression, and tumor promotion. Because of the potential for a unique mechanism of interaction with tumorgenesis, a Phase I trial of bryostatin-1 was performed in children with solid tumors to: (a) establish the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD); (b) establish the pharmacokinetic profile in children; and (c) document any evidence of antitumor activity. A 1-h infusion of bryostatin-1 in a PET formulation (60% polyethylene glycol 400, 30% ethanol, and 10% Tween 80) was administered weekly for 3 weeks to 22 children (age range, 2-21 years) with malignant solid tumors refractory to conventional therapy. Doses ranged from 20 to 57 microg/m2/ dose. Pharmacokinetics were performed in at least three patients per dose level. The first course was used to determine the DLT and MTD. Twenty-two patients on five dose levels were evaluable for toxicities. At the 57 microg/m2/dose level dose-limiting myalgia (grade 3) was observed in three patients; two of those patients also experienced photophobia or eye pain, and one experienced headache. Symptoms occurred in all patients within 24-72 h after the second dose of bryostatin-1 with resolution within 1 week of onset. Other observed toxicities (grades 1 and 2) included elevation in liver transaminases, thrombocytopenia, fever, and flu-like symptoms. The bryostatin-1 infusion was typically well tolerated. Although stable disease was noted in several patients, no complete or partial responses were observed. The recommended Phase II dose of bryostatin-1 administered as a 1-h infusion weekly for 3 of every 4 weeks to children with solid tumors is 44 microg/m2/dose. Myalgia, photophobia, or eye pain, as well as headache, were found to be dose limiting.  (+info)

p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. (4/250)

Although activation of protein kinase C (PKC) is known to promote cell survival and protect against cell death, the PKC targets and pathways that serve this function have remained elusive. Here we demonstrate that two potent activators of PKC, 12-O-tetradecanoylphorbol-13-acetate and bryostatin, both stimulate phosphorylation of Bad at Ser(112), a site known to regulate apoptotic cell death by interleukin-3. PKC inhibitors but not PI 3-kinase/Akt inhibitors block 12-O-tetradecanoylphorbol-13-acetate-stimulated Bad phosphorylation. PKC isoforms tested in vitro were unable to phosphorylate Bad at Ser(112), suggesting that PKC acts indirectly to activate a downstream Bad kinase. p90(RSK) and family members RSK-2 and RSK-3 are activated by phorbol ester and phosphorylate Bad at Ser(112) both in vitro and in vivo. p90(RSK) stimulates binding of Bad to 14-3-3 and blocks Bad-mediated cell death in a Ser(112)-dependent manner. These findings suggest that p90(RSK) can function in a PKC-dependent pathway to promote cell survival via phosphorylation and inactivation of Bad-mediated cell death.  (+info)

Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein. (5/250)

Enzyme localization often plays a controlling role in determining its activity and specificity. Protein kinase C (PKC) has long been known to translocate in response to physiological stimuli as well as to exogenous ligands such as the phorbol esters. We report here that different phorbol derivatives and related ligands, selected for differences in chemical structure and profile of biological activity, induce distinct patterns of redistribution of PKC delta. Localization of a PKC delta-green fluorescent protein (GFP) fusion construct was monitored in living Chinese hamster ovary cells as a function of ligand, concentration, and time using confocal laser scanning microscopy. delta-PKC-GFP was expressed predominantly in the cytoplasm, with some in the nucleus and perinuclear region. Phorbol 12-myristate 13-acetate (PMA) induced plasma membrane translocation followed by slower nuclear membrane translocation. As the concentration of PMA increased, the proportion of nuclear to plasma membrane localization increased markedly. In contrast to PMA, bryostatin 1, a unique activator of PKC that induces a subset of PMA-mediated responses while antagonizing others, at all doses induced almost exclusively nuclear membrane translocation. Like PMA, the complete tumor promoter 12-deoxyphorbol 13-tetradecanoate induced plasma membrane and slower nuclear membrane translocation, whereas the inhibitor of tumor promotion 12-deoxyphorbol 13-phenylacetate, which differs only in its side chain, induced a distinctive distribution of PKC delta-GFP. Finally, the novel constrained diacylglycerol derivative B8-DL-B8 induced a slow Golgi localization. We speculate that differential control of PKC delta localization may provide an interesting strategy for producing ligands with differential biological consequences.  (+info)

Proteolytic cleavage of protein kinase Cmu upon induction of apoptosis in U937 cells. (6/250)

Treatment of U937 cells with various apoptosis-inducing agents, such as TNFalpha and beta-D-arabinofuranosylcytosine (ara-C) alone or in combination with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), bryostatin 1 or cycloheximide, causes proteolytic cleavage of protein kinase Cmu (PKCmu) between the regulatory and catalytic domain, generating a 62 kDa catalytic fragment of the kinase. The formation of this fragment is effectively suppressed by the caspase-3 inhibitor Z-DEVD-FMK. In accordance with these in vivo data, treatment of recombinant PKCmu with caspase-3 in vitro results also in the generation of a 62 kDa fragment (p62). Treatment of several aspartic acid to alanine mutants of PKCmu with caspase-3 resulted in an unexpected finding. PKCmu is not cleaved at one of the typical cleavage sites containing the motif DXXD but at the atypical site CQND378/S379. The respective fragment (amino acids 379-912) was expressed in bacteria as a GST fusion protein (GST-p62) and partially purified. In contrast to the intact kinase, the fragment does not respond to the activating cofactors TPA and phosphatidylserine and is thus unable to phosphorylate substrates effectively.  (+info)

Differential roles of the tandem C1 domains of protein kinase C delta in the biphasic down-regulation induced by bryostatin 1. (7/250)

Bryostatin 1 (Bryo), currently in clinical trials, has been shown to induce a biphasic concentration-response curve for down-regulating protein kinase C (PKC) delta, with protection of the enzyme from down-regulation at high Bryo doses. In our ongoing studies to identify the basis for this unique behavior of PKCdelta, we examined the participation of the two ligand binding sites (C1a and C1b) in the regulatory domain of the enzyme. Three mutants of PKCdelta prepared by introducing a point mutation in either C1a or Clb or both C1a and Clb were overexpressed in NIH 3T3 cells. All of the constructs retained a biphasic response to down-regulation assessed after 24-h treatment with Bryo. However, the roles of the individual C1 domains were different for the two phases of the response. For down-regulation, both the C1a and the C1b mutants displayed equivalent 3-4-fold reductions in their affinities for the ligand. For protection from down-regulation, a reduced protection was observed for the C1a mutant, which showed a broader biphasic curve compared with those for wild-type PKCdelta and the Clb mutant. Like wild-type PKCdelta, all of the mutants showed the same subcellular partitioning of the protected enzyme to the particulate fraction of the cells, arguing against changes in sensitivity to Bryo due to differences in localization. Likewise, relatively similar patterns of localization were observed using green fluorescent protein-PKCdelta constructs. We conclude that the C1 domains of PKCdelta do not have equivalent roles in inducing protection against Bryo-induced down-regulation. The C1a domain plays a critical role in conferring the degree of protection at high concentrations of Bryo. Elucidation of the differential effect of Bryo on PKCdelta may suggest strategies for the design of novel ligands with Bryo-like activities.  (+info)

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (8/250)

Bryostatin 1 is a natural product isolated from the marine bryozoan Bugula neritina in 1982 and is currently undergoing evaluation in a number of malignancies. Twenty-five patients with relapsed, low-grade non-Hodgkin's lymphoma or chronic lyphocytic leukemia (CLL) received bryostatin 1 by 72-h continuous infusion every 2 weeks at a dose of 120 microg/m2 per course. Patients who progressed while receiving bryostatin 1 alone could participate in a feasibility study by receiving vincristine administered by bolus i.v. injection immediately after the completion of the bryostatin 1 infusion. The dose of vincristine was escalated in groups of three patients as follows: level 1, 0.5 mg/m2; level 2, 1.0 mg/m2; and level 3, 1.4 mg/m2 with vincristine doses capped at 2.0 mg for all patients. Bryostatin 1 alone resulted in one complete remission and two partial remissions. Nine patients received sequential treatment with bryostatin 1 and vincristine. The addition of vincristine at a dose of 2 mg was feasible and caused the expected dose-related sensory neuropathy. Phenotypic analysis by flow cytometric analysis on pre- and post-bryostatin 1-treated peripheral blood lymphocytes revealed up-regulation in the coexpression of CD11c/ CD22 on CD20+ B cells in two of four CLL patients studied, which is consistent with in vitro findings of differentiation of CLL cells to a hairy cell phenotype.  (+info)

TY - JOUR. T1 - Differential Effects of Bryostatins and Phorbol Esters on Arachidonic Acid Metabolite Release and Epidermal Growth Factor Binding in C3H 10T1/2 Cells. AU - DellAquila, Marie L.. AU - Herald, Cherry L.. AU - Kamano, Yoshiaki. AU - Pettit, George R.. AU - Blumberg, Peter M.. N1 - Copyright: Copyright 2016 Elsevier B.V., All rights reserved.. PY - 1988. Y1 - 1988. N2 - The bryostatins, a group of macrocyclk lactones isolated on the basis of their antineoplastic activity, activate protein kinase C in vitro and block phorbol ester binding to this enzyme. In some cellular systems, bryostatins mimic phorbol ester action. In other systems, however, the bryostatins display only marginal agonistic action and, instead, inhibit phorbol ester-induced responses. At least in primary mouse epidermal cells, a transient duration of action of bryostatin 1 could rationalize these differences. To determine whether this model of transient activation could explain the dual actions of bryostatin 1 in ...
Angewandte Chemie DOI: 10.1002/anie.200900109 Bryostatins Catalysis in the Total Synthesis of Bryostatin 16** Aubry K. Miller* bryostatins · homogeneous catalysis · lactones · macrocycles · total synthesis M acrocyclic secondary metabolites, perhaps best exemplified by the polyketide macrolactones, hold a special place in the history of natural product total synthesis. The exquisite biological potency and novel modes of action that many of these natural products possess, coupled with the fact that they often cannot be obtained in sufficient quantities for complete testing, has provided a clear need to develop efficient syntheses from robust chemical feedstocks. Notwithstanding the medicinal importance of these natural products, synthetic chemists have been awed by their intricate and imposing beauty, and inspired to recreate these compounds in the laboratory. Virtually all conceivable syntheses of a polyketide macrolactone require a macrocyclization step. In spite of the numerous methods ...
The main purpose of this study is find out how safe a single dose of bryostatin 1 is in patients with Alzheimers Disease (AD). This study is also being done 1) to determine how effective a single dose of bryostatin 1 is in the treatment of AD, 2) to find out what happens to bryostatin 1 once it enters the body by measuring the levels of bryostatin 1 in blood, and 3) to measure a substance in the blood (protein kinase C) that may help to better understand how bryostatin 1 works ...
A shock-and-kill approach involving the simultaneous treatment of HIV-1-infected patients with latency-reversing agents (LRAs) and combination antiretroviral therapy was proposed as a means to eradicate viral reservoirs. Currently available LRAs cannot discriminate between HIV-1-infected and uninfected cells. Therefore, the risks and benefits of using broad-spectrum LRAs need to be carefully evaluated, particularly in the CNS, where inflammation and leukocyte transmigration must be tightly regulated. We used a real-time impedance-sensing system to dynamically record the impact of different classes of LRAs on the integrity of tight monolayers of the immortalized human cerebral microvascular endothelial cell line hCMEC/D3. Results show that prostratin and bryostatin-1 can significantly damage the integrity of an endothelial monolayer. Moreover, prostratin and bryostatin-1 induce secretion of some proinflammatory cytokines and an increase of ICAM-1 expression. Additional studies demonstrated that ...
TY - JOUR. T1 - Effects of exercise and bryostatin-1 on serotonin dynamics after cerebral infarction. AU - Mizutani, Kenmei. AU - Sonoda, Shigeru. AU - Wakita, Hideaki. AU - Okazaki, Hideto. AU - Katoh, Yoshimitsu. AU - Chihara, Takeshi. AU - Shimpo, Kan. PY - 2016/6/15. Y1 - 2016/6/15. N2 - Although it has been suggested that the combination of exercise and bryostatin-1 administration may induce greater functional recovery than exercise alone, the detailed molecular mechanisms are not well known. Here, we examined the relationship between this combination treatment and monoamine dynamics in the cerebral cortex peri-infarction area to promote our understanding of these molecular mechanisms. Experimental cerebral cortex infarctions were produced by photothrombosis in rats. Voluntary exercise was initiated 2 days after surgery. Motor performance was then measured using the rotarod test. Monoamine concentrations in the perilesional cortex were analyzed by high-performance liquid chromatography. In ...
Abstract. We have examined the in vivo radioprotective effects of the macrocyclic lactone protein kinase C (PK-C) activator, bryostatin 1, administered either
OBJECTIVES:. I. Determine the response to bryostatin 1 (BRYO) administered weekly for 3 weeks in patients with relapsed non-Hodgkins lymphoma.. II. Assess the toxic effects of this treatment. III. Establish the correlation between PKC isoenzyme activity and BRYO function in lymphoma cells and normal lymphocytes.. IV. Determine the pharmacokinetic profile of BRYO and its relationship to pharmacodynamics.. OUTLINE:. Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.. ...
Phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibit the growth of A549 human lung carcinoma cells at non-toxic concentrations, whereas 1-oleoyl-2-acetylglycerol and 1,2-dioctanoylglycerol, synthetic analogues of the physiological ligands of protein kinase C (PKC), do not. Exper …
Researchers at the Blanchette Rockefeller Neurosciences Institute (BRNI) and the Marshall University Joan C. Edwards School of Medicine announced their findings from a new study entitled, PSEN1 Variant in a Family with Atypical AD. An Alzheimer patient with very severe disease, genetically confirmed to have a known variant of PSEN1, showed promising benefits during treatment with the drug Bryostatin 1. Genetically confirmed Alzheimers patients as severely advanced as patient IV-18 have not shown this level of clinical improvement previously with other treatment(s). We are very encouraged by the clinical improvements observed in patient IV-18. Nevertheless, controlled clinical trials are necessary to demonstrate safety and efficacy. BRNI believes, however, that this patients response is supportive evidence that activation of Protein Kinase C (PKC) by potent activators such as Bryostatin, with both pre-clinical synaptogenic and anti-amyloid efficacies, could be a viable therapeutic approach ...
We have been able to demonstrate in this patient that infusion of Bryo-1 for 72 h induces peripheral blood lymphocyte HC morphology and increases the sensitivity of cells to 2-CdA. Moreover, there was a significant reduction of lymphocyte count from 37.1 × 103/μl before the treatment to 3.4 × 103/μl, and partial remission was achieved 2 months after the treatment. Sequential treatment with Bryo-1 followed by 2-CdA induced the initiation of apoptosis.. Bryo-1 has been reported to induce differentiation of CLL cells of B-cell origin to a HC stage in vitro (2) . We have previously documented that Bryo-1-treated CLL cells exhibit increased sensitivity to 2-CdA, a drug active in treating de novo HCL but not active in fludarabine-resistant CLL. In WSU-CLL cells in vitro as well as the xenograft model in SCID mice, the efficacy of 2-CdA was enhanced when the cells were first exposed to Bryo-1 (6 , 7) . Administration of Bryo-1 followed by 2-CdA appeared to be sequence-dependent because neither ...
Để khích lệ tinh thần của những thành viên tâm huyết và những người có bài viết hay, hoặc những bài viết sưu tầm chất lượng, BQT quyết định : -- Những bài viết đó sẽ đc trang trọng đưa lên phần đầu diễn đàn, và đc dán lên cao tại Box có bài viết đó. -- Chủ nhân của những bài viết đó sẽ đc cộng điểm thưởng từ 1-|5 (tùy theo chất lượng bài viết). -- Người tìm và giới thiệu bài viết đó (nếu bài viết đó đc công nhận) sẽ đc cộng 2 điểm. -- Cuối tháng sẽ có đợt tổng kết và người có nhiều bài
Fingerprint Dive into the research topics of Activation and Growth of Murine Tumor-specific T-Cells Which Have in Vivo Activity with Bryostatin l. Together they form a unique fingerprint. ...
Giá bán lẻ 1 tuýp kem bôi nở ngực: 790.000 vnđ, hiện tại bạn mua 2 tuýp kem bôi nở ngực upsize chỉ 1 triệu đồng việt nam, Tiết kiệm lên đến 580.000 vnđ, đặt ngay: 0868900269
Giá bán lẻ 1 tuýp kem bôi nở ngực: 790.000 vnđ, hiện tại bạn mua 2 tuýp kem bôi nở ngực upsize chỉ 1 triệu đồng việt nam, Tiết kiệm lên đến 580.000 vnđ, đặt ngay: 0868900269
NF-κB作用机制。在此图中,将以Rel与p50蛋白组成的NF-κB异质二聚体为例。当处于激活状态时,NF-κB位于细胞质中且与抑制蛋白IκBα形成复合体。通过内在膜受体的介导,一些胞外信号物质可激活一种称为IκB激酶(IKK)的酶。IKK转而磷酸化IκBα蛋白,这将导致后者的泛素化,使得IκBα从NF-κB上脱离下来,最终IκBα被蛋白酶体所降解。被激活的NF-κB接下来转移到细胞核内,在这里会结合到DNA上被称为反应元件(RE)的特异性序列上。DNA/NF-κB 复合体接下来会招募其它蛋白,如辅激活物与RNA聚合酶,这些蛋白将下游的DNA转录为mRNA并转而被翻译为蛋白质,这些蛋白最终导致细胞功能发生改变[1][2][3] ...
2021年9月24日 - 合住房間 為$13。 The homestay in Muong Lo, Nghia Lo are houses on stilts. There are three houses which can accommodate up to hundred of travelers at the same time. ...
Kornax er lei andi v rumerki slandi til margra ra mj li fyrir b i bakstursi na inn og neytendamarka inn kk s traustum vi skiptavinum. Kornax er
TY - JOUR. T1 - Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix. T2 - A New York Gynecologic Oncology Group study. AU - Nezhat, Farr. AU - Wadler, Scott. AU - Muggia, Franco. AU - Mandeli, John. AU - Goldberg, Gary. AU - Rahaman, Jamal. AU - Runowicz, Carolyn. AU - Murgo, Anthony J.. AU - Gardner, Ginger J.. N1 - Funding Information: Supported by N01-CM-07003 from the National Cancer Institute, NIH. Previously presented in part at the American Society of Clinical Oncology, May 2002. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2004/4. Y1 - 2004/4. N2 - Objective. Bryostatin-1 is a macrocyclic lactone that has been shown to regulate protein kinase C (PKC) activity and thereby potentially inhibit tumor invasion, angiogenesis, cell adhesion, and multidrug resistance. In preclinical experiments, bryostatin-1 induces tumor growth inhibition and enhances cytotoxicity when combined with other agents including ...
TY - JOUR. T1 - A phase I study of intravenous bryostatin 1 in patients with advanced cancer. AU - Prendiville, J.. AU - Crowther, D.. AU - Thatcher, N.. AU - Woll, P. J.. AU - Fox, B. W.. AU - McGown, A.. AU - Testa, N.. AU - Stern, P.. AU - McDermott, R.. AU - Potter, M.. AU - Pettit, George. PY - 1993/8. Y1 - 1993/8. N2 - Bryostatin 1 is a novel antitumour agent derived from Bugula neritina of the marine phylum Ectoprocta. Nineteen patients with advanced solid tumours were entered into a phase I study to evaluate the toxicity and biological effects of bryostatin 1. Bryostatin 1 was given as a one hour intravenous infusion at the beginning of each 2 week treatment cycle. A maximum of three treatment cycles were given. Doses were escalated in steps from 5 to 65 micrograms m-2 in successive patient groups. The maximum tolerated dose was 50 micrograms m-2. Myalgia was the dose limiting toxicity and was of WHO grade 3 in all three patients treated at 65 micrograms m-2. Flu-like symptoms were ...
Read The Composition of fatty acids and aldehydes of the marine bryozoans Berenicea meandrina and Dendrobeania flustroides (Bryozoa: Gymnolaemata), Russian Journal of Marine Biology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
We sought to determine the res ponse rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced eso phageal cancer
Health,...Bryostatin may also work in patients with Alzheimers and traumatic in...WEDNESDAY Sept. 3 (HealthDay News) -- A little-used cancer drug calle... Current stroke treatments must be administered within three hours and... Todays stroke patient has precious minutes to receive care without s...,Drug,Given,24,Hours,After,Stroke,Helps,Repair,Brain,Tissue,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
The results of the present study indicate that although bryostatin 1 and UCN-01 share the capacity to interrupt the PKC signal transduction pathway and to promote ara-C-induced apoptosis, the mechanisms by which these two agents act differ fundamentally. There is abundant evidence that in hematopoietic cells, PKC exerts a cytoprotective function. For example, PKC activators such as PMA protect hematopoietic cells from growth factor deprivation-induced cell death (Lotem et al., 1991); in addition, pharmacologic PKC inhibitors are highly potent inducers of apoptosis in hematopoietic and nonhematopoietic cells (Jarvis et al., 1996). Moreover, PKC inhibitors have been shown to potentiate apoptosis induced by various cytotoxic drugs, including ara-C (Jarvis et al., 1994). Although bryostatin 1 acutely activates PKC, on long-term exposure it down-regulates the enzyme, a phenomenon that involves proteasomal degradation (Lee et al., 1997). Thus, under these circumstances, bryostatin 1 functions as a PKC ...
Our research program involves studies in chemistry, biology, and medicine. We place special emphasis on both the design of novel therapeutic drug candidates, and the development of new strategies for the efficient synthesis and evaluation of these molecules. The research supported by this grant is focused on molecules that are selected because of their unique biological activities and consequently their potential to lead to new therapeutics for treating cancer and other diseases.. One part of this program is directed at bryostatin, a marine natural product that is now in human clinical trials. Bryostatin has a unique range of activities, including the ability to trigger a programmed cell death pathway called apoptosis in cancer cells, providing a means to achieve selective elimination of cancer cells in the presence of normal cells. Bryostatin also reverses a cellular process called multidrug resistance that can allow cancer cells to neutralize the effects of entire classes of drugs; ...
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug ma
Fenestella, genus of extinct bryozoans, small colonial animals, especially characteristic of the Early Carboniferous Period (360 to 320 million years ago). Close study of Fenestella reveals a branching network of structures with relatively large elliptical openings and smaller spherical openings
krzem z borem silor b i inne produkty invex remedies - sklep - Sklep internetowy z naturalnymi suplementami diety w niskich cenach. Medycyna naturalna Immunocal, witaminy, krzem, vilcacora, noni itp. Promocja zdrowia - doradztwo zdrowotne i dietetyczne.
Pocket-sized and portable, Instant Work-ups: A Clinical Guide to Medicine offers all of the critical information physicians need to know in order to evaluate and diagnose a patient. The content is uniquely presented as a patient would present his or her case: with symptoms and abnormalities, as opposed to a diagnosis. Practical and easy to use, it provides clear work-up plans for the most commonly encountered medical conditions, providing quick, focused guidance with the flexibility to adapt to each unique patient.
G998B Dr.Ketan ROM ROM Features ROM Features varies with version of ROM. For more details, read changelog post. Link available in post #3 for...
Problem 11. Back and Forth Rows function b = back_and_forth(n) for i = 1:2:n b(i,:) = (i-1)*n+1:i*n; end for j = 2:2:n b(j,:) = j*n : -1 : (j-1)*n+1; end end Problem 12. Fibo
Bryostatin 1, a macrocyclic lactone isolated from a marine bryozoan, has significant antineoplastic activity against the murine cell line P388. Like phorbol esters, bryostain 1 is capable of binding to and activating protein kinase C, but these two compounds differ in the ability of bryostain 1 to act as a tumor promoter. We have investigated whether bryostatin 1 can modulate the differentiated phenotype of fresh samples of human myeloid leukemia. We find that six of seven samples responded to bryostatin treatment with changes associated with a more differentiated phenotype including increases in macrophage-like morphology and an increase in adherence and OKM1 and α-naphthyl acetate esterase activity positivity. The percentage of cells within each sample evidencing these changes varied markedly among the seven patients cells examined.. Because of the effects of bryostatin on fresh samples we examined the ability of bryostatin to differentiate four HL-60 cell sublines obtained from different ...
Technical Summary of BIMECTIN PLUS Injection for CATTLE - BIMEDA - ivermectin 1% + clorsulon 10%, macrocyclic lactone, benzenesulphonamide for the control of gastrointestinal roundworms, lungworms, eyeworms, liver flukes, lice, mites and grubs on cattle, cows, heifers, calves, bulls, bovine, Indications, spectrum of activity, recommended dose, safety, toxicity, LD50, withholding period, ingredientes, composición, administration, characteristics, features.
Technical Summary of MASTERMECTIN 10 mg/ml Solution for Injection for CATTLE, SHEEP & PIGS - C-CORP - ivermectin, macrocyclic lactone, for the control of gastrointestinal roundworms, lungworms, eyeworms, lice, mites and grubs on cattle, cows, heifers, calves, sheep, lambs, ewes, goats, swine, pigs, piglets. Indications, spectrum of activity, recommended dose, safety, toxicity, LD50, withholding period, ingredientes, composición, administration, characteristics, features.
SuperFluids™ CXP technology can be utilized to manufacture nutraceutical products such as saw palmetto for the treatment of mild to moderate benign prostate enlargement and St. Johns Wort for mild to moderate depression. Other candidate products include: ginseng used to boost mental and physical resistance to stress; ginkgo biloba used for increasing concentration and attention span as well as helping those suffering from Alzheimers; kava kava used to combat anxiety; and echinacea used for the prevention and treatment of colds and flu; as well as specialty flavors and fragrances. The technology can also be utilized to manufacture natural pharmaceuticals such as taxols, bryostatins and camptothecins ...
We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target. The initial rate of topoisomerase II phosphorylation was reduced 3-fold in K/VP.5 compared with K562 cells, but the rate of dephosphorylation was similar. Analysis of potential topoisomerase II protein kinases revealed a 3-fold reduction in the level of the beta II protein kinase C (PKC) in K/VP.5 cells, whereas levels of alpha- and epsilon PKC, casein kinase II, p42map kinase, and p34cdc2 kinase were comparable for both cell lines. The PKC activator, bryostatin 1, together with K562 nuclear extracts potentiated VP-16-induced topoisomerase II/DNA covalent complex formation in nuclei isolated from K/VP.5 cells but not from K562 cells. Bryostatin 1 effects were blocked by the PKC inhibitor 7-O-methyl-hydroxy-staurosporine. Bryostatin 1 also up-regulated ...
Background Regression of established tumors can be induced by adoptive immunotherapy with tumor draining lymph node lymphocytes activated with bryostatin and ionomycin. We hypothesized that tumor regression is mediated by a subset of the transferred T lymphocytes, which selectively infiltrate the tumor draining lymph nodes and proliferate in vivo. Results Adoptive transfer of B/I activated tumor draining lymphocytes induces regression of advanced 4T1 tumors, and depletion of CD8, but not CD4 T cells, abrogated tumor regression in mice. The predominant mediators of tumor regression are CD8+ and derived from CD62L- T cells. Transferred lymphocytes reached their peak concentration (10.5%) in the spleen 3 days after adoptive transfer and then rapidly declined. Adoptively transferred cells preferentially migrated to and/or proliferated in the tumor draining lymph nodes, peaking at day 5 (10.3%) and remained up to day 28. CFSE-stained cells were seen in tumors, also peaking at day 5 (2.1%). Bryostatin and
Free Online Library: Evolutionary and structural diversification of the larval nervous system among marine bryozoans.(Report) by The Biological Bulletin; Biological sciences Bryozoa Physiological aspects Research Bryozoans Larval development Nervous system
Phase I (one) medical and clinical trial recruitment. Volunteer to join trials or advertise a clinical trial or medical study on MedTrials.
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
On a day trip to walk to the wonderful hermitage in Perthshire, a watery wonderland where the autumn leaves are a bit past their best. The bryophytes, though, are luscious, and I couldnt resists snagging a couple even though I was off duty. Favourite of the day was Bazzania trolobata, which I have wanted to see for a while. One of those things you see in the field guide and look forward to meeting it ...
A seaweed-like marine invertebrate contains a molecule that has piqued interest as a drug but is in short supply: Collecting 14 tons of the critters, a type of bryozoan, yields just 18 grams of the potential medicine. Now, an efficient lab recipe might make bryostatin 1 easier to get.. Making more of the molecule could help scientists figure out whether the drug - which has shown mixed.... ...
Trepostomata, extinct order of bryozoans (moss animals) found as fossils in marine rocks of Ordovician to Triassic age (200 million to 488 million years old). The trepostomes are characterized by colonies in long, curved calcareous tubes, the interiors of which are intersected by partitions. The
Bài Tập Về Đại Từ Nhân Xưng - Free download as Word Doc (.doc / .docx), PDF File (.pdf), Text File (.txt) or read online for free. kjkk
Bài viết liên quan đến Rêu này vẫn còn sơ khai. Bạn có thể giúp Wikipedia bằng cách mở rộng nội dung để bài được hoàn chỉnh hơn. ...
Informácie získané prostredníctvom Google reCAPTCHA podliehajú Pravidlám ochrany osobných údajov a Zmluvným podmienkam spoločnosti Google a používajú sa všeobecné bezpečnostné účely (nepoužívajú sa na prispôsobenú reklamu spoločnosti Google ...
Informácie získané prostredníctvom Google reCAPTCHA podliehajú Pravidlám ochrany osobných údajov a Zmluvným podmienkam spoločnosti Google a používajú sa všeobecné bezpečnostné účely (nepoužívajú sa na prispôsobenú reklamu spoločnosti Google ...
Bài viết tông cúc Heliantheae này vẫn còn sơ khai. Bạn có thể giúp Wikipedia bằng cách mở rộng nội dung để bài được hoàn chỉnh hơn. ...
I have no problems with my face. But |b|I am very fond of attractive jaw lines|/b|. My jawline is very normal. Can I undergo surgery for those awesome looks, with the hot jawlines? How much would such a surgery cost?
|em|Previously published; newly revised by author|br||br|I like my women like I like my whiskey: liable to kill me.|/em||br||br|The two parts of being a paranormal private investigator I could really...|/em||/strong||/b||/i|
|br||i||b|To purchase this product, you must be an established patient of Epi Center MedSpa. Please call our office for further details.|/br||/b||/i| |br|Available only through a doctor, LATISSE® is a once-daily prescription treatment applied to the ba
positive variable xplus(j), xneg(j); obj.. z=e=sum(j, xplus(j) + xneg(j)); cons(i).. sum(j, a(i,j)*(xplus(j) - xneg(j))) =l= b(i); model foo /all/; solve foo minimizing z using lp ...
Bryostatins are potent modulators of protein kinase C. They have been studied in clinical trials as anti-cancer agents, as anti ... Bryostatins are a group of macrolide lactones from the marine organism Bugula neritina that were first collected and provided ... As of 2010 20 different bryostatins had been isolated. The low concentration in bryozoans (to extract one gram of bryostatin, ... Total syntheses have been published for bryostatins 1, 2, 3, 7, 9 and 16. Among them, Wender's total synthesis of bryostatin 1 ...
Bryostatins were first isolated from Bryozoa. Salinosporamides are derived from Salinispora tropica. Ziconotide is derived from ...
"The Bryostatins' Tale", Chemical and Engineering News 89.43, October 24, 2011, pp. 10-17 Manning, Thomas J.; Land, Michael; ... "Identifying bryostatins and potential precursors from the bryozoan 'Bugula neritina'", Natural Product Research 19.5 (2005) 467 ... "Identifying bryostatins and potential precursors from the bryozoanBugula neritina". Natural Product Research. 19 (5): 467-491. ...
... produces the bryostatins, a group of around twenty bioactive natural products. The bryostatins are under investigation for ... Ruan BF, Zhu HL (2012). "The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development". Curr ...
A group of chemicals called bryostatins can be extracted from the marine bryozoan Bugula neritina. In 2001 pharmaceutical ...
The Saksena-Evans reduction has since been used in the synthesis of several products, particularly the bryostatins. Evans- ...
Certain antineoplastic agents, bryostatins 4 and 5, have been extracted from Aplidium californicum and are being evaluated. ...
... neritina attracted interest as a source of cytotoxic chemicals, bryostatins, under clinical investigation as anti-cancer ... B The Bryostatins' Tale Chemical and Engineering News, Vol 89, No 43 PP. 10 - 17 Oct 24, 2011 accessed Dec 19, 2017 "Bryostatin ...
Throughout his career, he pursued the total synthesis of complex natural products, culminating in his work on bryostatins. Keck ...
Using this strategy, Pettit and his research group discovered multiple anti-cancer compounds, including bryostatins, ...
... and the bryostatins (from the bryozoan Bugula neritina). Natural products sometimes have pharmacological activity that can be ...
"The Bryostatins' Tale", Chemical and Engineering News 89.43, October 24, 2011, pp. 10-17 Gordon, R. Sharov, AA Eds. (2017). ... "Identifying bryostatins and potential precursors from the bryozoan 'Bugula neritina'", Natural Product Research 19.5 (2005) 467 ...
Bryostatins were first isolated in the 1960s from bugula. To date, 20 different bryostatins have been identified. They are ... Bugula and Bryostatins. Often mistaken for seaweed, bugula is actually colonies of small animals, like coral. It has been found ...
Bryostatins are potent modulators of protein kinase C. They have been studied in clinical trials as anti-cancer agents, as anti ... Bryostatins are a group of macrolide lactones from the marine organism Bugula neritina that were first collected and provided ... As of 2010 20 different bryostatins had been isolated. The low concentration in bryozoans (to extract one gram of bryostatin, ... Total syntheses have been published for bryostatins 1, 2, 3, 7, 9 and 16. Among them, Wenders total synthesis of bryostatin 1 ...
Effects of Bryostatins and Retinoic Acid on Phorbol Ester- and Diacylglycerol-induced Squamous Differentiation in Human ... Our results indicate that the bryostatins and retinoids affect the multistep process of squamous differentiation in ...
TY - JOUR. T1 - Bryostatin 1, an activator of protein kinase c, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. AU - Gschwendt, M.. AU - Fürstenberger, G.. AU - Rose-john, S.. AU - Rogers, M.. AU - Kittstein, W.. AU - Pettit, George. AU - Herald, C. L.. AU - Marks, F.. N1 - Funding Information: This work is dedicated to Professor W.Kunz on the occasion of his 65th birthday. The ASU-CR1 component received financial support from the Fannie E.Rippel Foundation, the Arizona Disease Control Research Commssion, the Robert B.Dalton Endowment Fund, and PHS Grants CA-16049-07-11 awarded by the National Cancer Institute, DHHS; and for other necessary assistance we wish to thank Drs John E.Leet and Yoshiakj Kamano.. PY - 1988/4. Y1 - 1988/4. N2 - The macrocyclic lactone bryostatin 1 activates protein kinase C as effectively as the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA). Nevertheless, there are only certain TPA-effects that can be induced by ...
DAVIDSON, S.; ALLEN, S.; LIM, G.; ANDERSON, C. and HAYGOOD, M. (2001). Evidence for the biosynthesis of bryostatins by the ... bryostatins, a family of macrocyclic lactones with anticancer activity (Davidson et al. 2001). Finally, EF0705 (EF657868) and ...
Bryostatins Retain Promise. (October 24, 2011 , Vol. 89 Issue 43 , pp. 10-17) New results in total synthesis reinvigorate a 40- ...
A preliminary evaluation of a metathesis approach to bryostatins . Tetrahedron Letters. 47. (13). p. 2223-2227. ... fragment of the bryostatins . Tetrahedron Letters. 45. (47). p. 8737-8740. ...
Bryostatins. 2. + 177. Phosphatidylinositol 3-Kinases. 2. + 178. DNA Primers. 2. + 179. NK Cell Lectin-Like Receptor Subfamily ...
Esquivel, J., Sticca, R., Sugarbaker, P., Levine, E., Yan, T. D., Alexander, R., Baratti, D., Bartlett, D., Barone, R., Barrios, P., Bieligk, S., Bretcha-Boix, P., Chang, C. K., Chu, F., Chu, Q., Daniel, S., De Bree, E., Deraco, M., Dominguez-Parra, L., Elias, D., & 55 othersFlynn, R., Foster, J., Garofalo, A., Gilly, F. N., Glehen, O., Gomez-Portilla, A., Gonzalez-Bayon, L., Gonzalez-Moreno, S., Goodman, M., Gushchin, V., Hanna, N., Hartmann, J., Harrison, L., Hoefer, R., Kane, J., Kecmanovic, D., Kelley, S., Kuhn, J., LaMont, J., Lange, J., Li, B., Loggie, B., Mahteme, H., Mann, G., Martin, R., Misih, R. A., Moran, B., Morris, D., Onate-Ocana, L., Petrelli, N., Philippe, G., Pingpank, J., Pitroff, A., Piso, P., Quinones, M., Riley, L., Rutstein, L., Saha, S., Alrawi, S., Sardi, A., Schneebaum, S., Shen, P., Shibata, D., Spellman, J., Stojadinovic, A., Stewart, J., Torres-Melero, J., Tuttle, T., Verwaal, V., Villar, J., Wilkinson, N., Younan, R., Zeh, H., Zoetmulder, F. & Sebbag, G., Jan 2007, ...
Dive into the research topics of Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis‐diamminedichloroplatinum(II). Together they form a unique fingerprint. ...
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties ...
Bryostatins are medicinally important macrolides discovered from the cosmopolitan bryozoan Bugula neritina (2). Twenty ... bryostatins, which all possess a 20-membered ring, are known to date. Bryostatin 1 (33) showed good antitumor activity; it ...
Other antitumor agents derived from marine sources include eleutherobin, discodermolide, bryostatins, dolostatins, and ...
A group of chemicals called bryostatins can be extracted from the marine bryozoan Bugula neritina. In 2001 pharmaceutical ...
Twenty-one Bryoid compositions, known as Bryostatins and numbered 1-21, have been identified. Many of these Bryoids are known ... Bryoids consist of a family of Bryostatins, such as Bryostatin-1, that are complex cyclic macrolide molecules. Bryoids were ...
or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. ...
Childers WE, Havran LM, Asselin M, Bicksler JJ, Chong DC, Grosu GT, Shen Z, Abou-Gharbia MA, Bach AC, Harrison BL, Kagan N, Kleintop T, Magolda R, Marathias V, Robichaud AJ, Sabb AL, Zhang MY, Andree TH, Aschmies SH, Beyer C, Comery TA, Day M, Grauer SM, Hughes ZA, Rosenzweig-Lipson S, Platt B, Pulicicchio C, Smith DE, Sukoff-Rizzo SJ, Sullivan KM, Adedoyin A, Huselton C, Hirst WD. The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists. J Med Chem. 2010 May 27; 53(10):4066-84 ...
Bryostatins: Selected Syntheses Biological Activity, and Analogue Design. Total Synthesis of Cortistatin A ...
... exiguolide and the B ring in bryostatins. ... exiguolide and the B ring in bryostatins. ...
Define bryony. bryony synonyms, bryony pronunciation, bryony translation, English dictionary definition of bryony. n. pl. bry·o·nies 1. Any of various Eurasian tendril-bearing vines of the genus Bryonia, having red or black berries and tuberous roots formerly used as...
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C. M., Roberts, A. W., Jurczak, W., Mulligan, S. P., Böttcher, S., Mobasher, M., Zhu, M., Desai, M., Chyla, B., Verdugo, M., Enschede, S. H., Cerri, E., Humerickhouse, R., & 3 othersGordon, G., Hallek, M. & Wierda, W. G., Jun 1 2016, In: The Lancet Oncology. 17, 6, p. 768-778 11 p.. Research output: Contribution to journal › Article › peer-review ...
Bryostatins 25% * COLON CANCER PREVENTION PROGRAM PROJECT. Einspahr, J. G., Alberts, S., Roe, D., Moon, D., Rathje, W., Green, ...
Davidson, S.K., Allen, S.W., Lim, G.E., Anderson, C.M. y Haygood, M.G. (2001). Evidence for the biosynthesis of bryostatins by ...
Marine natural products: bryostatins in preclinical and clinical studies. Ruan and Zhu. 2012. The chemistry and biology of the ... An even bigger problem is how can we possibly meet the demand for bryostatins from this one species. A promising solution to ... Bugula neritina, also known as brown bryozoans and common bugulas, produce chemicals called "bryostatins" which could be used ... this supply problem would be to develop synthetic copies that work just like bryostatins and can be easily mass produced, but ...
These results indicate that bryostatins activate T-cells through PK-C.. AB - Bryostatins are macrocyclic lactones isolated from ... Bryostatins bind and activate protein kinase C (PK-C), the cellular receptor for the phorbol esters, and elicit PK-C-dependent ... Bryostatins bind and activate protein kinase C (PK-C), the cellular receptor for the phorbol esters, and elicit PK-C-dependent ... Bryostatins bind and activate protein kinase C (PK-C), the cellular receptor for the phorbol esters, and elicit PK-C-dependent ...
MeSH Terms: Bryostatins; Cell Differentiation/drug effects; Culture Media; Dose-Response Relationship, Drug; Humans; Lactones/ ...
Bryostatins / pharmacology* Actions. * Search in PubMed * Search in MeSH * Add to Search ...
Bryostatins: Panacea?. Posted By David Kroll on Oct 24, 2011. I just had the delightful pleasure of participating in the C&EN ... Chemical & Engineering News 89(43): 10-17 (24 October 2011) Cover story - The Bryostatins Tale Profile on George (Bob) Pettit ... the bryostatins. These complex compounds were originally studied for anticancer activities but, as Bethany tells us, are now ...
To date 20 different bryostatins has been isolated, those are currently under investigation as anti-cancer agents [91, 92]. ... Diethylaminoethyl chitosan induces apoptosis in HeLa cells via activation of caspase-3 and p53 expression [90]. Bryostatins are ... Bryostatins Inhibits various cancer types and [91] currently used in clinical trials Eribulin Microtubule inhibitor and ... Bryostatins Macrolides Bryozoan (Bugula neritina) Eribulin Macrolide Halichondria okadai mesylate and Axinella family (E7389) ...
Bryostatins Preferred Term Term UI T692456. Date02/28/2007. LexicalTag NON. ThesaurusID NLM (2008). ... Bryostatins Preferred Concept UI. M0507120. Registry Number. 0. Scope Note. A group of 20-member macrolactones in which there ... Bryostatins. Tree Number(s). D02.540.576.500.937. Unique ID. D054713. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/D054713 ...
Bryostatins Preferred Term Term UI T692456. Date02/28/2007. LexicalTag NON. ThesaurusID NLM (2008). ... Bryostatins Preferred Concept UI. M0507120. Registry Number. 0. Scope Note. A group of 20-member macrolactones in which there ... Bryostatins. Tree Number(s). D02.540.576.500.937. Unique ID. D054713. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/D054713 ...
Bertero, T., Cottrill, K. A., Lu, Y., Haeger, C. M., Dieffenbach, P., Annis, S., Hale, A., Bhat, B., Kaimal, V., Zhang, Y. Y., Graham, B. B., Kumar, R., Saggar, R., Saggar, R., Wallace, W. D., Ross, D. J., Black, S. M., Fratz, S., Fineman, J. R., Vargas, S. O. & 5 others, Haley, K. J., Waxman, A. B., Chau, B. N., Fredenburgh, L. E. & Chan, S. Y., Nov 3 2015, In: Cell Reports. 13, 5, p. 1016-1032 17 p.. Research output: Contribution to journal › Article › peer-review ...
The natural products that are currently the focus of my research are the bryostatins, a group of compounds with anticancer and ...
... gly217 striate arg353gln striata nitroxyethyl kusnezoffii ruin ruii helgolandensis carbocyanines scaffolds isomolar bryostatins ...
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2022 Elsevier B.V. 弊社は、サービスを提供、向上し、コンテンツをカスタマイズするために、Cookieを使用しま
Dive into the research topics of Bryostatin 1 induces biphasic activation of protein kinase D in intact cells. Together they form a unique fingerprint. ...
Synthesis of Bryostatins. 1. Construction of the C(1)-C(16) Fragment. Journal of Organic Chemistry, 54, 2817-2825 (1989).. ...
Bryostatins Medicine & Life Sciences 94% * Transcription Factor AP-1 Medicine & Life Sciences 67% ...
5. Identification and Biological Activities of Bryostatins from Japanese Bryozoan. Ueno, S., R.C. Yanagita, K. Murakami, A. ...
... bryostatins, sarcodictyin and cytarabine from marine organisms and bleomycin and doxorubicin from micro-organisms (dactinomycin ... bryostatins, sarcodictyin and cytarabine from marine organisms and bleomycin and doxorubicin from micro-organisms (dactinomycin ...
Blue N0000166474 Bromthymol Blue N0000179057 bronopol N0000170884 Brucella Vaccine N0000178894 brucine N0000178792 Bryostatins ...
Animals, Antineoplastic Agents, Bryostatins, DNA Topoisomerases, Type I, Drug Resistance, Enzyme Inhibitors, Humans, Lactones, ...
Bryostatins D2.540.505.112 D2.540.576.500.937 Buddleja B1.650.940.800.575.100.892.124 B1.650.940.800.575.100.583.800.124 ...
... bryophyte bryophytes Bryopsis Bryopsis cinicola Bryopsis hypnoides Bryopsis maxima Bryopsis plumosa bryostatin bryostatins ...
... and T863 2-chimaerin are indeed high affinity receptors for the phorbol esters and also for the bryostatins, macrocyclic ...
Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, Venkataraman S, Mackey MA, Flanagan SW, Oberley LW, Spitz DR. Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem. 2005 Feb 11; 280(6):4254-63 ...
Bryostatins Bryozoa BTB-POZ Domain Buchnera Bucladesine Bucrylate Budd-Chiari Syndrome Buddhism Buddleja Budesonide Budesonide ...
  • To date, 20 different bryostatins have been identified. (fraxa.org)
  • As of 2010 20 different bryostatins had been isolated. (wikipedia.org)
  • Bryostatins are a group of macrolide lactones from the marine organism Bugula neritina that were first collected and provided to JL Hartwell's anticancer drug discovery group at the National Cancer Institute (NCI) by Jack Rudloe. (wikipedia.org)
  • Bryoids consist of a family of Bryostatins, such as Bryostatin-1, that are complex cyclic macrolide molecules. (prdistribution.com)
  • Bryostatins are macrocyclic lactones isolated from the marine bryozoan Bugula neritina. (elsevier.com)
  • We previously have reported that 1- and T863 2-chimaerin are indeed high affinity receptors for the phorbol esters and also for the bryostatins, macrocyclic lactones with antitumor properties (11, 12). (afl-journal.org)
  • The natural products that are currently the focus of my research are the bryostatins, a group of compounds with anticancer and neurological activity that is produced by the uncultured microbial endosymbiont "Candidatus Endobugula sertula," of the temperate marine bryozoan, Bugula neritina. (openwetware.org)
  • 5. Identification and Biological Activities of Bryostatins from Japanese Bryozoan . (nih.gov)
  • Bryostatins bind and activate protein kinase C (PK-C), the cellular receptor for the phorbol esters, and elicit PK-C-dependent cellular functions. (elsevier.com)
  • A few examples of anti-cancer agents of natural origin include vincristine, vinblastine, paclitaxel, camptothecin and topotecan obtained from plants, bryostatins, sarcodictyin and cytarabine from marine organisms and bleomycin and doxorubicin from micro-organisms (dactinomycin, bleomycin and doxorubicin). (eurekaselect.com)